grepafloxacin (Raxar)

structure in first source

Also Known As:

Raxar; (+--)-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; (+--)-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid monohydrochloride; 3-quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-; 3-quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-, monohydrochloride, (+--)-; OPC 17116; OPC-17116; grepafloxacin HCl; grepafloxacin hydrochloride

Networked: 76 relevant articles (12 outcomes, 20 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - grepafloxacin: 76
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Quinolones: 2938
        Fluoroquinolones: 5348
        grepafloxacin: 76

Experts

1.	Atkins, Helen S: 3 articles (07/2010 - 11/2009)
2.	Brooks, Timothy J G: 3 articles (07/2010 - 11/2009)
3.	Sefton, Armine M: 3 articles (07/2010 - 11/2009)
4.	Simpson, Andrew J H: 3 articles (07/2010 - 11/2009)
5.	Yamaguchi, Hiroaki: 2 articles (01/2014 - 02/2004)
6.	Kenny, Dermot J: 2 articles (07/2010 - 11/2009)
7.	Bregante, M A: 2 articles (11/2005 - 11/2003)
8.	Honrubia, F M: 2 articles (11/2005 - 11/2003)
9.	Pinilla, I: 2 articles (11/2005 - 11/2003)
10.	Solans, C: 2 articles (11/2005 - 11/2003)

Related Diseases

1.	Pneumonia (Pneumonitis) 03/01/1998 - "In an open study, grepafloxacin was also effective in treating atypical pneumonia caused by Mycoplasma pneumoniae and Legionella pneumophila. " 03/01/1998 - "Studies in community-acquired pneumonia (CAP) have compared grepafloxacin, 600 mg o.d. " 09/01/1997 - "The efficacy and safety of grepafloxacin in treating patients with community-acquired pneumonia (CAP) was assessed in an open-label, noncomparative study. " 09/01/1997 - "Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia." 03/01/1998 - "The maximum plasma concentrations and area under the concentration---time curve achieved with grepafloxacin suggest that it will be effective for the treatment of community-acquired pneumonia and acute exacerbations of chronic bronchitis. "
2.	Infections 01/01/1997 - "Grepafloxacin also appears to be highly effective against extragenital infections." 03/01/1998 - "Results from clinical trials so far indicate that grepafloxacin has a broad spectrum of activity covering all important community-acquired respiratory pathogens, and may be suitable for the empirical treatment of respiratory infection." 09/01/1992 - "aureus were 1:2. These data would suggest that an 800-mg dose of OPC-17116 taken orally once daily would provide adequate concentrations to treat infections due to the pathogens examined in this study." 06/01/2004 - "The activity of grepafloxacin in two murine models of Mycobacterium avium infection." 09/01/2003 - "Grepafloxacin potency and spectrum of activity were re-evaluated against contemporary pathogens collected from clinical infections in 2001-2002. "
3.	Respiratory Tract Infections (Respiratory Tract Infection) 04/01/1999 - "CONCLUSIONS: Grepafloxacin showed effective antibacterial activity against the Legionella spp. tested, and has a PAE and activity within human monocytes that suggest it may be useful in the treatment of lower respiratory tract infections caused by Legionella spp." 03/01/1998 - "Clinical efficacy and tolerability of grepafloxacin in lower respiratory tract infection." 12/01/1997 - "Grepafloxacin--focus on respiratory infections." 02/01/1995 - "A clinical role for OPC-17116 is suggested in a wide range of respiratory infections, including those due to intracellular bacteria." 10/01/1994 - "Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections."
4.	Chronic Bronchitis 11/01/2000 - "Forty nine subjects with acute bacterial exacerbations of chronic bronchitis (ABECB) treated with grepafloxacin were evaluated for parameters predictive of clinical outcome. " 01/01/1999 - "Three hundred eighty-nine patients were enrolled in a double-masked, multicenter, randomized clinical trial comparing the clinical and bacteriologic efficacies and safety of a 5-day course (n = 195) versus a 10-day course (n = 194) of grepafloxacin 400 mg once daily in the treatment of acute bacterial exacerbations of chronic bronchitis (ABECB). " 12/01/1997 - "This analysis was designed to characterize the population pharmacokinetics and pharmacodynamics of oral grepafloxacin (OPC-17,116) in patients with acute bacterial exacerbations of chronic bronchitis (ABECB). " 12/01/1997 - "Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis." 01/01/1999 - "Effectiveness of short-course therapy (5 days) with grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis."
5.	Staphylococcal Infections 04/01/2000 - "Gemifloxacin was also effective against staphylococcal infection, as were grepafloxacin and levofloxacin, while ciprofloxacin, trovafloxacin and tosufloxacin were significantly less effective against these pathogens than gemifloxacin (P < 0.01). "

Related Drugs and Biologics

1.	Ciprofloxacin (Cipro)
2.	Ofloxacin (Ofloxacine)
3.	Cefixime (Suprax)
4.	Quinolones
5.	trovafloxacin
6.	tosufloxacin
7.	Fluoroquinolones
8.	Amoxicillin (Wymox)
9.	Levofloxacin (Levaquin)
10.	Enoxacin (AT 2266)

Related Therapies and Procedures

1.	Therapeutics
2.	Intravenous Administration
3.	Intravitreal Injections
4.	Intravenous Injections
5.	Intravenous Infusions